Drug Profile
Research programme: topical pain therapeutics - Sienna Biopharmaceuticals
Alternative Names: CT750Latest Information Update: 16 Dec 2016
Price :
$50
*
At a glance
- Originator Creabilis SA
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Anaesthesia
Most Recent Events
- 06 Dec 2016 Creabilis SA has been acquired by Sienna Biopharmaceuticals
- 16 Jul 2016 No recent reports of development identified for research development in Anaesthesia in Luxembourg (Topical)